SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 83.90+36.0%Nov 7 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen10/7/2004 12:51:02 PM
  Read Replies (2) of 347
 
GenoMed to Offer Nationwide Influenza Trial

CONTACT: GenoMed Inc. David W. Moskowitz, MD, MA, FACP (314) 983-9933 dwmoskowitz@genomedics.com

ST. LOUIS, MO. – October 7, 2004 – GenoMed, Inc. (Pink Sheets: GMED), a Next Generation DM™ (Disease Management) company that uses its expertise in genomics to improve clinical outcomes, announced today that it will offer its patent-pending broad spectrum viral antidote to the nation during the coming flu season this fall and winter.

Because of difficulties that a major pharmaceutical company has experienced at a British factory, nearly half of the flu vaccine doses destined for the U.S. will not be delivered in time for this year's flu season. U.S. health authorities have already begun planning how to ration existing flu vaccine doses.

GenoMed has applied for patent protection on the use of a class of blood pressure medications in viral diseases, such as the flu. This is a totally novel approach. There is no shortage of these medications worldwide.

The Company has had 100% success in treating a small number of normal, immunocompetent patients suffering from West Nile virus encephalitis during the past two summers, including the elderly. GenoMed's first case series of eight patients was published in July, 2004 in Current Topics in Medicinal Chemistry, a peer-reviewed medical journal.

Both the White House Office of Science Technology & Policy and the Department of Homeland Security have expressed interest in GenoMed's potential broad-spectrum viral antidote. GenoMed will be meeting during October with the National Institute of Allergy and Infectious Diseases (NIAID) to discuss further testing of its approach against viral diseases, including influenza.

About GenoMed

GenoMed is leading the clinical revolution which medical genomics has already made possible. GenoMed is currently marketing its protocol for preventing kidney failure due to high blood pressure and diabetes, and delaying emphysema. GenoMed's influenza trial will be Internet-based, like its current West Nile virus trial. Click here to enroll in the flu trial: b2i.us
To enroll in GenoMed's West Nile trial, click on the "West Nile trial" link at GenoMed's website, www.genomed.com.
.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext